Patterns of Epstein-Barr Virus Latent and Replicative Gene Expression in Epstein-Barr Virus B Cell Lymphoproliferative Disorders After Organ Transplantation

Réa, Delphine; Fourcade, C.; Leblond, Véronique; Rowe, Martin; Joab, Irène; Edelman, L; Bitker, Marc‐Olivier; Gandjbakhch, I; Suberbielle, Caroline; Farcet, Jean‐Pierre; Raphaël, Martine

doi:10.1097/00007890-199408000-00012

Cited by 85 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies conducted on EBV lytic proteins or gene products in patients with PTLD are scanty and are related mostly to the role of EBV proteins and gene products in neoplastic tissues [11][12][13]; these studies show variable proportions of expression rates, which obviously cannot be compared with results in PBLs. In our cohort, transcripts of BZLF1 were detected in ∼70% of the patients (at a rate comparable to those found by others [13] in PBLs of immunocompetent patients with infectious mononucleosis or in PBLs of EBV healthy carriers).…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of Epstein‐Barr Virus Genome Copy Number andBZLF1Expression in Blood Lymphocytes of Transplant Recipients at Risk for Lymphoproliferative Disease

et al. 2000

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) genome numbers and RNA transcripts from the immediate-early EBV gene BZLF1 were monitored by means of polymerase chain reaction in peripheral blood lymphocytes (PBLs) of 44 children who received liver transplants. The 2 tests were compared, using several parameters to assess their value as predictors of posttransplantation lymphoproliferative disease (PTLD). All patients were infected with EBV. BZLF1 mRNA was positive in 70% of patients, with highest expression in those with largest virus load. Four patients developed PTLD that could not be unequivocally diagnosed by any of the parameters considered alone. Sensitivity of EBV genome number (>/=40,000 EBV copies/10(5) PBLs) and BZLF1 mRNA (BZLF1:glyceraldehyde-3-phosphate-dehydrogenase ratio >/=0.5) was 100%. Specificity of each of the 2 tests alone (98% and 58%, respectively) improved (to 100% and 83%, respectively) when measurement of serum IgG level was included. Because decreased virus load, but not BZLF1 mRNA expression, accurately predicted favorable responses of PTLD to therapy, monitoring of EBV genome numbers alone appears sufficient in children with liver transplants.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive Value of Epstein‐Barr Virus Genome Copy Number andBZLF1Expression in Blood Lymphocytes of Transplant Recipients at Risk for Lymphoproliferative Disease

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Taking into account the extremely elevated loads that were reported using real-time PCR in some PTLD patients, but also in patients with EBV reactivation, this viral DNA in plasma may represent EBV virions. It is known that a small number of PTLD cells may show lytic EBV infection [10,12,13]. Alternatively, plasma EBV DNA could represent viral DNA released from cells damaged in vivo or ex vivo.…”

Section: Origin Of Elevated Ebv Dna Loads In Blood Of Ptld Patientsmentioning

confidence: 99%

Role of Epstein-Barr Virus DNA Load Monitoring in Prevention and Early Detection of Post-transplant Lymphoproliferative Disease

Stevens¹,

Verschuuren²,

Verkuujlen³

et al. 2002

Leukemia & Lymphoma

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disease (PTLD) is a severe and life-threatening complication after stem cell or solid-organ transplantation, virtually always associated with presence of Epstein-Barr virus (EBV) in the proliferating cells. PTLD is probably caused by the iatrogenically impaired T-cell response allowing outgrowth of EBV-positive B-cells. Quantitative EBV DNA load monitoring is a minimally invasive technique increasingly recognized as a valuable tool in posttransplant patient management. In this review, we focus on the clinical utility of EBV DNA load monitoring in the peripheral blood of transplant recipients using PCR and we discuss the currently most-widely used techniques and their value and limitations in predicting and diagnosing PTLD. Options for EBV DNA load-guided pre-emptive therapy and application of monitoring EBV DNA load dynamics in the prediction of clinical response after therapy are described. Origins of elevated EBV DNA loads in immunosuppressed patients and recent insights in the EBV life cycle in the immuncompromised host are discussed. Finally, a standardization of methodology, clinical specimen type, and cut-off values is proposed. This is essential for comparisons between different institutes and more adequate patient management.

show abstract

“…Characteristically, EBV-induced LPD in recipients with transplantation show a type III latency, although there is considerable variability. A large proportion of these LPD also supports lytic infection, usually in a small subset of cells [66]. In addition to the severe combined immunode® ciency mouse model as xenotransplantation, EBV-induced LPD in recipients with transplantation provide evidence that EBV may be truly the etiologic agent inducing malignant lymphoproliferation in humans [67].…”

Section: Lymphoproliferative Disorders In Patients With Immunode Ciencymentioning

confidence: 99%

FROM BURKITT'S LYMPHOMA TO CHRONIC ACTIVE EPSTEIN-BARR VIRUS (EBV) INFECTION: An Expanding Spectrum of EBV-Associated Diseases

Okano¹,

Gross²

2001

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Epstein-Barr virus (FBV) is one of 8 known human herpesviruses. EBV infection usually occurs in early childhood and is subclinical. However, primary infection in adolescence or adulthood causes infectious mononucleosis in approximately half of infected individuals. Recently, the spectrum of human diseases associated with EBV injection has increased, primarily due to methodological advances in EBV detection. Initially, EBV was isolated from a cultured Burkitt lymphoma cell line, and has been felt to be etiologically linked to the development of Burkitt lymphoma, as well as other human malignancies. This review mainly focuses on pathogenetic mechanisms, many of which remain enigmatic, for the various human diseases, which are considered to be associated with EBV injection.

show abstract

Patterns of Epstein-Barr Virus Latent and Replicative Gene Expression in Epstein-Barr Virus B Cell Lymphoproliferative Disorders After Organ Transplantation

Cited by 85 publications

References 0 publications

Predictive Value of Epstein‐Barr Virus Genome Copy Number andBZLF1Expression in Blood Lymphocytes of Transplant Recipients at Risk for Lymphoproliferative Disease

Predictive Value of Epstein‐Barr Virus Genome Copy Number andBZLF1Expression in Blood Lymphocytes of Transplant Recipients at Risk for Lymphoproliferative Disease

Role of Epstein-Barr Virus DNA Load Monitoring in Prevention and Early Detection of Post-transplant Lymphoproliferative Disease

FROM BURKITT'S LYMPHOMA TO CHRONIC ACTIVE EPSTEIN-BARR VIRUS (EBV) INFECTION: An Expanding Spectrum of EBV-Associated Diseases

Contact Info

Product

Resources

About